{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"107"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"40"},{"groupId":"BG007","value":"42"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"12"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"249"}],"units":"Participants"}],"groups":[{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 milligram per kilogram (mg/kg) infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG000","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG001","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG002","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG003","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg"},{"description":"Participants with a broader variety of hematologic malignancies and selected solid tumors, received a 0.2 mg/kg/week TTI-621 infusion until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG004","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) Monotherapy"},{"description":"Participants with cHL received 0.1 mg/kg/week TTI-621 infusion along with 3 mg/kg nivolumab given every 2 weeks or a fixed dose per current FDA approved package insert for cHL.If required dose of TTI-621 could be increased up to 0.5 mg/kg/week. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"BG005","title":"Part 2: Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination"},{"description":"Participants with CD20-positive malignancies received 0.1 mg/kg/week TTI-621 infusion along with 375 mg/m\\^2 rituximab given weekly (1 cycle) for up to 8 cycles according to the institutional standard of care. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"BG006","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination"},{"description":"Participants with CTCL and PTCL, received a 0.2 mg/kg/week TTI-621 infusion. Initial 2 weeks of 0.2 mg/kg treatment followed by intraparticipant dose intensification at an increment of 0.1 mg/kg per week up to 0.5 mg/kg within 5-8 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG007","title":"Part 3: Ontorpacept (PF-07901800/TTI-621) Monotherapy"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG008","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG009","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG010","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG011","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG012","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"BG013","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg"},{"description":"Total of all reporting groups","id":"BG014","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"52"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"19"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"7"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"130"}],"title":"< 65 Years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"36"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"11"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"74"}],"title":"65 - < 75 Years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"4"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"43"}],"title":"75 - < 85 Years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"2"}],"title":">= 85 Years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"46"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"18"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"96"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"61"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"24"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"10"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"153"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"26"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"94"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"34"},{"groupId":"BG007","value":"32"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"11"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"209"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"14"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"14"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"28"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"85"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"31"},{"groupId":"BG007","value":"30"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"9"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"191"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Analysis population included all the participants who received at least one dose of study treatment."}